Search Results
May 05, 2026, 08:05 ET AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
NORTH CHICAGO, Ill., May 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW) Annual Meeting, May 2-5
More news about: AbbVie
Apr 30, 2026, 09:00 ET Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month
IRVINE, Calif., April 30, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, today announced a charitable initiative in recognition of Skin Cancer Awareness Month. Throughout May, the company will donate $10 to The Skin
More news about: AbbVie
Apr 29, 2026, 07:47 ET AbbVie Reports First-Quarter 2026 Financial Results
pharmacodynamics of ABBV-295, in adults with a mean body mass index (BMI) of less than 30 kg/m2. In the study, ABBV-295 treatment showed clinically meaningful body weight reduction at week 12 (weekly dosing) and week 13 (every other week and monthly dosing after week 5). ABBV-295 also demonstrated
More news about: AbbVie
Apr 28, 2026, 08:00 ET AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata
NORTH CHICAGO, Ill., April 28, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted an application for a new indication to the U.S. Food and Drug Administration (FDA) for upadacitinib (RINVOQ®;
More news about: AbbVie
Apr 27, 2026, 08:05 ET AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
inductionNORTH CHICAGO, Ill., April 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® (risankizumab-rzaa)
More news about: AbbVie
Apr 23, 2026, 16:05 ET AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.
mannerNORTH CHICAGO, Ill., April 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application
More news about: AbbVie
Apr 22, 2026, 12:02 ET AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus
2028NORTH CHICAGO, Ill., April 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced a $1.4 billion investment to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina. The state-of-the-art campus
More news about: AbbVie
Apr 19, 2026, 18:00 ET Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
binding and internalization compared with a parental monoclonal antibody alone, and compared with clinical-stage ADC, ABBV-706Greater inhibition of cell viability compared with ABBV-706 in cell lines with varying SEZ6 expressionProduces tumor regressions at doses as low as 2 mg/kg in small
More news about: Whitehawk Therapeutics, Inc.
Apr 14, 2026, 08:50 ET Erin Lichy Gets Real About Her Natrelle® Breast Augmentation
IRVINE, Calif., April 14, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) has teamed up with New York-based entrepreneur and television personality, Erin Lichy. Lichy is opening up about her recent breast augmentation with
More news about: AbbVie
Apr 13, 2026, 02:24 ET Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain
Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants AbbVie the exclusive rights to develop, manufacture, and commercialize novel
More news about: Haisco
Apr 12, 2026, 07:15 ET AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
NORTH CHICAGO, Ill., April 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that late-breaking results from the Phase 2 IMGN853-0420 trial will be presented in an oral session at the 2026 Society of Gynecologic
More news about: AbbVie
Apr 08, 2026, 08:00 ET BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year
IRVINE, Calif., April 8, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced that applications are now open for
More news about: AbbVie
Apr 07, 2026, 09:00 ET Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin
IRVINE, Calif., April 7, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, today announced the opening of the new AMI Austin in Texas. This location marks the third U.S. AMI Training Center opened in the past year
More news about: Allergan Aesthetics, an AbbVie company
Mar 31, 2026, 10:04 ET /C O R R E C T I O N -- AbbVie/
IRVINE, Calif., March 31, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its fourth annual CoolMonth, featuring exclusive offers on CoolSculpting®, the treatment doctors use most for nonsurgical fat
More news about: AbbVie
Mar 31, 2026, 08:00 ET AbbVie to Host First-Quarter 2026 Earnings Conference Call
NORTH CHICAGO, Ill., March 31, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2026 financial results on Wednesday, April 29, 2026, before the market opens. AbbVie will host a live webcast of the earnings
More news about: AbbVie
Mar 27, 2026, 10:00 ET AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting
NORTH CHICAGO, Ill., March 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new research across its dermatology portfolio to be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, March
More news about: AbbVie
Mar 24, 2026, 08:00 ET AbbVie Named Official Pharmaceutical Partner of Major League Baseball
impactNORTH CHICAGO, Ill., March 24, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced a multi-year partnership with Major League Baseball (MLB), naming AbbVie the Official Pharmaceutical Partner of MLB beginning with the
More news about: AbbVie
Mar 19, 2026, 03:00 ET Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions
IRVINE, Calif., March 19, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and global leader in medical aesthetics, today announced new global consumer research highlighting how patient expectations in medical aesthetics are
More news about: AbbVie
Mar 11, 2026, 17:31 ET Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight
rise in the launch of emerging therapies such as Azetukalner (Xenon Pharmaceuticals), Elunetirom (ABX-002) (Autobahn Therapeutics), ABBV-932 and Icalcaprant (ABBV-1354) (AbbVie), ALTO-100 (Alto Neuroscience), NRX-101 (NRx Pharmaceuticals), LB-102 (LB Pharmaceuticals), and others and healthcare spending
More news about: DelveInsight Business Research, LLP
Mar 11, 2026, 11:45 ET REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
(RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV
More news about: REGENXBIO Inc.
Mar 09, 2026, 08:00 ET AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
ABBV-295 treatment showed clinically meaningful body weight reduction from -7.75% to -9.79% (least-squares mean) at week 12 (weekly dosing), to -7.86% to -9.73% at week 13 (every other week and monthly dosing after week 5)1ABBV-295 demonstrated a favorable tolerability
More news about: AbbVie
Mar 05, 2026, 07:05 ET REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
2026Robust patient enrollment continues in confirmatory trialSurabgene lomparvovec (sura-vec, ABBV-RGX-314) subretinal wet AMD topline pivotal data expected in Q4 2026; first patient dosed in pivotal Phase IIb/III trial in diabetic retinopathy expected
More news about: REGENXBIO Inc.
Mar 04, 2026, 07:05 ET REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
(RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV
More news about: REGENXBIO Inc.
Mar 03, 2026, 08:00 ET AbbVie to Present at the Leerink Partners Global Healthcare Conference
NORTH CHICAGO, Ill., March 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026. Management will participate in a fireside chat at 10:20
More news about: AbbVie
Mar 02, 2026, 08:30 ET AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease
observed1NORTH CHICAGO, Ill., March 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety
More news about: AbbVie